Biochemical and body weight changes with metformin in polycystic ovary syndrome.

Abstract

OBJECTIVE:

To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syndrome (PCOS).

METHOD:

Fifteen obese PCOS patients that attended the university clinic were included to this prospective study. These patients used 1,500 mg of metformin daily for 12 months.

RESULT:

We found a statistically different decrease in mean body mass index (t:4,369), (p:0.0002) at the end of the 12 months. In contrast to that there were no statistical differences in fasting serum insulin and testosterone levels. Metformin improved menstrual patterns (60% of cases) in obese PCOS patients.

CONCLUSION:

Hyperinsulinemia and androgen excess in obese non-diabetic women with PCOS are not improved by the administration of metformin. Metformin treatment may have improved menstrual patterns by a mechanism independent of and unrelated to insulin sensitivity or circulating insulin concentrations.

• Authors: B Baysal, M Batukan, C Batukan
• Journal: Clinical and experimental obstetrics & gynecology (Clin Exp Obstet Gynecol) Vol. 28 Issue 4 Pg. 212-4 ( 2001) ISSN: 0390-6663 [Print] Singapore
• PMID: 11838739 (Publication Type: Journal Article)

Chemical References

• Hypoglycemic Agents
• Insulin
• Testosterone
• Metformin

Topics

• Adult
• Body Weight (drug effects)
• Female
• Humans
• Hypoglycemic Agents (pharmacology)
• Insulin (blood)
• Menstruation
• Metformin (pharmacology)
• Obesity (complications, physiopathology)
• Polycystic Ovary Syndrome (blood, complications, physiopathology)
• Prospective Studies
• Testosterone (blood)